Altre lingue Eisai Co., Ltd.

Azioni

4523

JP3160400002

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
6.240 ^JPY	-0,30%		+7,14%	-11,51%

24/04	Biogen batte le stime sugli utili trimestrali, le vendite del farmaco per l'Alzheimer aumentano	RE
23/04	L'adozione del farmaco per l'Alzheimer negli Stati Uniti è rallentata dallo scetticismo dei medici	RE

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	25/04
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024	24/04
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	24/04
Alzheimer's drug adoption in US slowed by doctors' skepticism	23/04
BioArctic and Eisai sign research evaluation agreement regarding BAN2802	20/04
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)	18/04
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan	17/04
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?	13/04
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics	03/04
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	01/04
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01/04
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01/04
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	01/04
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01/04
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical	29/03
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture	29/03
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024	29/03
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	25/03
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22/03
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	22/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Eisai Co., Ltd.

Azioni

4523

JP3160400002

Altre lingue

Filtri